Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates.
about
The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patientsPharmGKB summary: very important pharmacogene information for UGT1A1Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingIrinotecan pharmacogenomicsLineage-Specific Changes in Biomarkers in Great Apes and HumansUGT genotyping in belinostat dosingEffect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteersDose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.Genetic influences on serum bilirubin in American Indians: The Strong Heart Family StudyAssociation between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants.Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in AfricansIs there diversity among UGT1A1 polymorphism in Japan?The role of pharmacogenetics in cancer therapeutics.Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.Pharmacogenomics and histone deacetylase inhibitors.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
P2860
Q21559550-FE3B2B19-1ED2-46DA-8AF3-DEF9EEF0EBFEQ24562836-1FF11DAF-0673-4623-8BC7-2BD79C6C5236Q26784507-0F2263AC-6A9A-46D7-88F6-5BCE4D4C72B9Q28287024-D36692BC-ADE7-4788-AA43-C3420F7EC9ABQ28547060-EEE8B39B-3DFE-4C98-9667-55F5D9B4B888Q33429235-E198C647-1B75-4F17-8434-F404BDFDDB5DQ33554432-657543E6-0478-4F50-892C-EEBE9744A1E5Q33927990-7D79FACE-A862-4B02-B915-DDA1C73CFDFBQ34614162-C716631E-8254-4D59-A4E6-8B0BED2D5CFFQ34629650-78274B3E-BC00-40C7-AD92-E3504B1602C6Q35108890-D9A169F6-5D2B-4691-B51E-0E0D7256F5D6Q35258583-72713DF6-EE2F-4DDE-8AB0-DBF5682A6582Q36120735-691CA7D6-5ADB-4986-8A46-205AAE4C808AQ36536674-82236967-4D82-427B-8236-F0DEC7EA0E73Q36813326-C057DC6E-62C8-40C3-B987-EE133A96DC45Q37096874-3438EEBA-D3A2-4864-9259-38AC99629AD6Q37180144-08974844-408D-4B37-A065-B9D5E38C84A8Q37685527-E2EF60DB-3064-4B59-BA5E-4520D7328DEEQ37712297-61D890D1-A259-4FA4-A8BB-C3B670AF5274Q38987332-178E3604-F8CD-449B-9892-492625A33B8AQ52362144-D60AAD21-9279-44E7-BAB2-D060D856CA9A
P2860
Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Variability at the uridine dip ...... uman populations and primates.
@en
Variability at the uridine dip ...... uman populations and primates.
@nl
type
label
Variability at the uridine dip ...... uman populations and primates.
@en
Variability at the uridine dip ...... uman populations and primates.
@nl
prefLabel
Variability at the uridine dip ...... uman populations and primates.
@en
Variability at the uridine dip ...... uman populations and primates.
@nl
P2093
P1476
Variability at the uridine dip ...... human populations and primates
@en
P2093
Destro-Bisol G
Di Rienzo A
Petzl-Erler ML
P304
P577
1999-10-01T00:00:00Z